Clinical trials: Crohn's Disease Colon
Crohn's Disease, Colitis
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to…
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Trial name
- NCT01369355
- Testing
- Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Where
- 220 sites in United States, Australia and 24 more
- Volunteers
- 1,282 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases
ImmuneSense™ IBD Study
This study will enroll adult and pediatric participants across 3 phases: Research phase, Clinical Validation (CV) and Analytical Validation (AV) phase.
- Trial name
- NCT05769829
- Where
- 6 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Crohn's Disease, Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Trial name
- NCT01369342
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 220 sites in United States, Australia and 20 more
- Volunteers
- 640 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Inflammatory Bowel Diseases (IBD)
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory…
- Trial name
- NCT07544160
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- iCell Gene Therapeutics
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Inflammatory Bowel Disease
Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
The purpose of the study is to evaluate the PK, safety and tolerability of PF-06687234 and [124I]IB-PF-06687234 (simultaneously given) in subjects with moderate to severe Ulcerative Colitis or Crohn's Disease.
- Trial name
- NCT03414788
- Testing
- PF 06687234, [124I]IB PF 06687234
- Where
- United States
- Sponsor
- Pfizer
Colitis, Ulcerative, Crohn Disease
A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate how long participants with moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC) continue treatment with guselkumab in a real-world setting.
- Trial name
- GALILEO (NCT07848737)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag, S.A.
Systemic Lupus Erythematosus, Sjogren's Syndrome
Cell Surface Marker Expression in Autoimmune Diseases
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) systemic sclerosis, (e) Crohn's…
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis
- Trial name
- CASCADE (NCT03757065)
- Where
- 2 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Alpine Immune Sciences, Inc.
Ulcerative Colitis, Crohn's Disease
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon.
- Trial name
- NCT06581042
- Where
- 11 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- AbbVie
Ulcerative Colitis, Crohn's Disease
Predicting Medication Response for Autoimmune Disease
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients.
- Conditions
- Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
- Trial name
- REEF (NCT04995783)
- Testing
- Coral FRS test
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Coral Genomics, Inc.
Arthritis, Rheumatoid, Spondylitis, Ankylosing
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease
- Trial name
- PERFUSE (NCT03662919)
- Testing
- Infliximab, Adalimumab
- Where
- 60 sites in France
- Volunteers
- 2,274 people
- Sponsor
- Biogen
Crohn Disease, Colitis, Ulcerative
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC).
- Trial name
- NCT06651281
- Testing
- Tulisokibart
- Where
- 37 sites in United States, Czechia and 5 more
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease, Colitis, Ulcerative
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
The purpose of this study is to assess the effectiveness of ustekinumab on extra-intestinal manifestations (EIMs) and immune-mediated inflammatory diseases (IMIDs) associated with inflammatory bowel disease (IBD) (both Crohn's…
- Trial name
- TENOR (NCT03606499)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Janssen Cilag S.A.S.
Ulcerative Colitis, Crohn's Disease
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain.
- Trial name
- PANORAMA (NCT06581328)
- Testing
- Vedolizumab IV, Vedolizumab SC
- Where
- 101 sites in United States
- Volunteers
- 200 people
- Sponsor
- Takeda
Inflammatory Bowel Disease (IBD)
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
This is an exploratory, open-label, uncontrolled, multi-center, 1-arm study conducted at 16 sites in Bulgaria, Germany and Romania. A total of ca.
- Trial name
- ENTRANCE (NCT00820365)
- Testing
- SC12267 (4SC-101)
- Where
- 16 sites in Bulgaria, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- 4SC AG
Crohn's Disease
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
The purpose of this study is to assess long-term safety data of GED-0301 for a period of up to 208 weeks in adult subjects (i.e., ≥ 18 years of age) who participated in the core Phase 3 GED-0301-CD-002 and GED-0301-CD-003 studies…
- Trial name
- NCT02641392
- Testing
- GED-0301
- Where
- 231 sites in United States, Australia and 29 more
- Volunteers
- 310 people
- Sponsor
- Celgene
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Crohn's Disease, Ulcerative Colitis
An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen
This is a study of the electronical dosing tool MedicPen and it's qualities with regards to user friendliness and medication compliance.
- Trial name
- NCT00917514
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Medicpen AB